Cargando…

PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer

Detalles Bibliográficos
Autor principal:	Liang, Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196060/ https://www.ncbi.nlm.nih.gov/pubmed/35676753 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0244

Ejemplares similares

Conversion Surgery for Stage IV Gastric Cancer
por: Zhang, Fei, et al.
Publicado: (2019)

Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification
por: Yoshida, Kazuhiro, et al.
Publicado: (2015)

The long-term survival of stage IV gastric cancer patients with conversion therapy
por: Yamaguchi, Kazuya, et al.
Publicado: (2017)

Conversion surgery for stage IV gastric cancer: a multicenter retrospective study
por: Kano, Yosuke, et al.
Publicado: (2022)

International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1)
por: Yoshida, Kazuhiro, et al.
Publicado: (2021)

Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
por: Beom, Seung-Hoon, et al.
Publicado: (2018)

Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
por: Watanabe, Hayato, et al.
Publicado: (2021)

The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy
por: Shin, Min-Kyue, et al.
Publicado: (2023)

Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report
por: Matsumoto, Ryu, et al.
Publicado: (2020)

Continuing and new roles for surgery in the management of patients with stage IV melanoma
por: Friedman, Erica B, et al.
Publicado: (2018)

PD-1 inhibitors in endometrial cancer
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2017)

Temporal dynamics from phosphoproteomics using endoscopic biopsy specimens provides new therapeutic targets in stage IV gastric cancer
por: Hirano, Hidekazu, et al.
Publicado: (2022)

Clinical high risk for psychosis provides new opportunities for schizophrenia intervention strategies
por: Wang, Jijun, et al.
Publicado: (2022)

The neutrophil/lymphocyte ratio as a predictor of successful conversion surgery for stage IV gastric cancer: a retrospective study
por: Nakamura, Naohiko, et al.
Publicado: (2020)

Molecular and Cellular Therapies: New challenges and opportunities
por: Wang, Xiangdong, et al.
Publicado: (2013)

Does Stage at Diagnosis Affect Prognosis of Patients With Stage IV Breast, Lung, and Colorectal Cancers?
por: Kiely, Belinda E
Publicado: (2018)

Tumor microenvironment characterization in stage IV gastric cancer
por: Yang, Feng, et al.
Publicado: (2021)

Impact of breast surgery in de novo stage IV breast cancer
por: Shien, Tadahiko
Publicado: (2019)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
por: Liu, Ye, et al.
Publicado: (2021)

PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer
por: Wang, Yali, et al.
Publicado: (2021)

The Combination of Seven Preoperative Markers for Predicting Patients with Gastric Cancer to Be Either Stage IV or Non-Stage IV
por: Ge, Wei, et al.
Publicado: (2018)

New Opportunities
por: Heintzel, Alexander
Publicado: (2020)

Paradigm Shift in the Treatment of Elderly Patients With Unresectable Stage IV Colorectal Cancer
por: Kim, Nam Kyu
Publicado: (2014)

CT-based delta radiomics in predicting the prognosis of stage IV gastric cancer to immune checkpoint inhibitors
por: Li, Jiazheng, et al.
Publicado: (2023)

Stage IV Gastric Cancer: The Surgical Perspective of the Italian Research Group on Gastric Cancer
por: Ministrini, Silvia, et al.
Publicado: (2020)

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment
por: Serratì, Simona, et al.
Publicado: (2023)

PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
por: Gou, Miaomiao, et al.
Publicado: (2023)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

Primary Tumor Resection in Stage IV Breast Cancer: Consistent Benefit, or Consistent Bias?
por: Khan, Seema A.
Publicado: (2007)

Is noncurative gastrectomy always a beneficial strategy for stage IV gastric cancer?
por: Lee, Chang Min, et al.
Publicado: (2017)

Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report
por: Fukuda, Kosuke, et al.
Publicado: (2022)

An overview of biomass conversion: exploring new opportunities
por: Fülöp, László, et al.
Publicado: (2020)

New Jersey’s Opportunity
Publicado: (1900)

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
por: Mo, Dun-Chang, et al.
Publicado: (2022)

Primary Tumor Resection and Survival in Patients with Stage IV Gastric Cancer
por: Müsri, Fatma Yalçin, et al.
Publicado: (2016)

A Predictive Nomogram for Early Mortality in Stage IV Gastric Cancer
por: Feng, Yuqian, et al.
Publicado: (2020)

Missed Opportunities for Providing Low-Fat Dietary Advice to People With Diabetes
por: Lobo, Ingrid E., et al.
Publicado: (2012)

Psychological Distress Persists Among COVID-19 Health Care Providers, Suggesting New Challenges and Missed Opportunities for Support
por: Eaton England, Ashley, et al.
Publicado: (2021)

Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma
por: Teng, Junjie, et al.
Publicado: (2022)

Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
por: Wojtukiewicz, Marek Z., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fuunun9vlhqtttr0g5t7ua68bt